Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
10
Expiration
Dec 24, 2026
DTE
41d
Moneyness
OTM
Intrinsic
$0.00
IBRX 10 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.15 | -57.14% | 39 | 497 |
| Nov 20, 2026 | 7d | $0.33 | -49.23% | 108 | 8,626 |
| Nov 27, 2026 | 14d | $0.45 | -16.67% | 25 | 321 |
| Dec 4, 2026 | 21d | $0.95 | +35.71% | 1 | 360 |
| Dec 11, 2026 | 28d | $0.95 | +23.38% | 1 | 19 |
| Dec 18, 2026 | 35d | $0.65 | -25.29% | 41 | 541 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.87 | -30.40% | 194 | 68,056 |
| Mar 19, 2027 | 126d | $1.35 | -15.63% | 50 | 1,560 |
| Apr 16, 2027 | 154d | $1.45 | +1.40% | 55 | 397 |
| May 21, 2027 | 189d | $1.73 | -14.36% | 4 | 108 |
| Aug 20, 2027 | 280d | $3.48 | +2.35% | 8 | 414 |
| Nov 19, 2027 | 371d | $2.36 | +5.83% | 7 | 76 |
| Jan 21, 2028 | 434d | $2.50 | -14.38% | 147 | 18,863 |
| Mar 17, 2028 | 490d | $3.30 | -5.71% | 5 | 416 |
| Jan 19, 2029 | 798d | $3.75 | +0.27% | 36 | 2,792 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.